Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary CNS Lymphoma

Condition:   Non-hodgkin Lymphoma Interventions:   Drug: Methotrexate;   Drug: Rituximab (where available);   Drug: Ibrutinib Sponsors:   Canadian Cancer Trials Group;   Janssen Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials